Literature DB >> 9303368

Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis.

G Ferrandina1, G Scambia, F Bardelli, P Benedetti Panici, S Mancuso, A Messori.   

Abstract

Several reports have evaluated the correlation between cathepsin-D and overall survival or disease-free survival in node-negative breast cancer patients. Because conflicting data have so far been reported, a meta-analysis was conducted to clarify this problem. Eleven studies were included in our meta-analysis (total of 2690 patients). A specific meta-analytical methodology for censored data was used, and disease-free survival was the primary end point. Patients with low cathepsin-D levels had a significantly better disease-free survival than patients with high cathepsin-D values (meta-analytical odds ratio from 0.59 to 0.60 over the interval from 1 to 7 years). A secondary meta-analysis conducted exclusively on the data from eight studies based on cytosol assay gave substantially similar results. One limitation of our study is that the cut-off values to define high and low cathepsin-D concentrations were not identical in the various studies included in our meta-analysis (range from 20 to 78 pmol mg(-1) protein), thus introducing a possible bias in the statistical analysis of the data. However, a simulation based on the well-accepted method of the so-called publication bias showed that more than 100 null studies would be required to lead our results to a statistical level of non-significance. Considering the results of our meta-analysis, we conclude that the data presently available confirm a statistically significant association between high cathepsin-D values and poor disease-free survival in node-negative breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303368      PMCID: PMC2228021          DOI: 10.1038/bjc.1997.442

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  39 in total

Review 1.  Why sources of heterogeneity in meta-analysis should be investigated.

Authors:  S G Thompson
Journal:  BMJ       Date:  1994-11-19

2.  Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis.

Authors:  A Messori; C Brignola; G Trallori; R Rampazzo; G Bardazzi; C Belloli; G d'Albasio; G De Simone; N Martini
Journal:  Am J Gastroenterol       Date:  1994-05       Impact factor: 10.864

3.  Relapse following discontinuation of antiepileptic drugs: a meta-analysis.

Authors:  A T Berg; S Shinnar
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

4.  Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay.

Authors:  P Roger; P Montcourrier; T Maudelonde; J P Brouillet; A Pages; F Laffargue; H Rochefort
Journal:  Hum Pathol       Date:  1994-09       Impact factor: 3.466

5.  Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays.

Authors:  T E Kute; Z M Shao; N K Sugg; R T Long; G B Russell; L D Case
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

6.  Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer.

Authors:  P M Ravdin; A K Tandon; D C Allred; G M Clark; S A Fuqua; S H Hilsenbeck; G C Chamness; C K Osborne
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

7.  The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group.

Authors:  R Seshadri; D J Horsfall; F Firgaira; K McCaul; V Setlur; A H Chalmers; R Yeo; D Ingram; H Dawkins; R Hahnel
Journal:  Int J Cancer       Date:  1994-01-02       Impact factor: 7.396

8.  Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay.

Authors:  P Eng Tan; C C Benz; C Dollbaum; D H Moore; S M Edgerton; D T Zava; A D Thor
Journal:  Ann Oncol       Date:  1994-04       Impact factor: 32.976

9.  Prognostic significance of cathepsin-D in patients with breast cancer.

Authors:  J H Winstanley; S J Leinster; T G Cooke; B R Westley; A M Platt-Higgins; P S Rudland
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

10.  Stromal cell cathepsin D expression and long-term survival in breast cancer.

Authors:  H Joensuu; S Toikkanen; J Isola
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more
  31 in total

Review 1.  Prognostic factors in breast cancer: current and new predictors of metastasis.

Authors:  D F Hayes; C Isaacs; V Stearns
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

2.  Overexpression of both catalytically active and -inactive cathepsin D by cancer cells enhances apoptosis-dependent chemo-sensitivity.

Authors:  M Beaujouin; S Baghdiguian; M Glondu-Lassis; G Berchem; E Liaudet-Coopman
Journal:  Oncogene       Date:  2006-03-23       Impact factor: 9.867

Review 3.  Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.

Authors:  Attiqa N Mirza; Nadeem Q Mirza; Georges Vlastos; S Eva Singletary
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

4.  Post-operative nomogram for predicting freedom from recurrence after surgery in localised breast cancer receiving adjuvant hormone therapy.

Authors:  Chafika Mazouni; Frédéric Fina; Sylvie Romain; Pascal Bonnier; L'houcine Ouafik; Pierre-Marie Martin
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

Review 5.  Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

6.  Association of ICAM-1, VCAM-1, CYCLIN D1 and Cathepsin D with Clinicopathological Parameters in Breast Carcinoma; an Immunohistochemical Study.

Authors:  Özgür Külahcı; H Hasan Esen; Elife Asut; Salim Güngör
Journal:  J Breast Health       Date:  2017-01-01

7.  Procathepsin D and cancer: From molecular biology to clinical applications.

Authors:  Vaclav Vetvicka; Aruna Vashishta; Sujata Saraswat-Ohri; Jana Vetvickova
Journal:  World J Clin Oncol       Date:  2010-11-10

8.  Cathepsin D is partly endocytosed by the LRP1 receptor and inhibits LRP1-regulated intramembrane proteolysis.

Authors:  D Derocq; C Prébois; M Beaujouin; V Laurent-Matha; S Pattingre; G K Smith; E Liaudet-Coopman
Journal:  Oncogene       Date:  2011-11-14       Impact factor: 9.867

9.  Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth.

Authors:  Mélanie Beaujouin; Christine Prébois; Danielle Derocq; Valérie Laurent-Matha; Olivier Masson; Sophie Pattingre; Peter Coopman; Nadir Bettache; Jami Grossfield; Robert E Hollingsworth; Hongyu Zhang; Zemin Yao; Bradley T Hyman; Peter van der Geer; Gary K Smith; Emmanuelle Liaudet-Coopman
Journal:  J Cell Sci       Date:  2010-09-07       Impact factor: 5.285

Review 10.  Cathepsin D--many functions of one aspartic protease.

Authors:  Petr Benes; Vaclav Vetvicka; Martin Fusek
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-08       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.